DEINOVE is active in the search for novel anti-infective molecules and the development of new generations of drugs capable of responding to the global challenge of antibiotic resistance, a major health threat:
- Building a portfolio of first-in-class antibiotic candidates, which places it among the major players in the field, by bringing together a global network of expertise (Morphochem, bioMérieux, Naicons, Medpace),
- Preparing the entry into Phase II of a first antibiotic candidate targeting severe gastrointestinal infections caused by Clostridium difficile.
- Systematically exploring a targeted biological diversity to supply its portfolio with new leads. This program called AGIR - Antibiotics against Resistant Infectious Germs - is supported by Bpifrance and conducted in collaboration with the Institut Charles Viollette of Lille (University of Lille I).